U.S., Oct. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07858526) titled 'Optimised Dalbavancin Dosing for Serious Gram-Positive Bacterial Infections' on Sept. 09.
Brief Summary: Serious infections caused by gram-positive bacteria often require several weeks of antibiotic treatment, which may involve prolonged hospitalisation, intravenous treatment and long-term vascular access. Dalbavancin is a long-acting antibiotic that can be given less frequently than conventional intravenous antibiotics.
EDGAR is a multicentre prospective observational study involving up to 50 adults receiving dalbavancin as part of routine clinical care for serious gram-positive infections. The decision to prescribe dalbavancin, in...